John Dawson CBE Appointed to Ergomed Board as NED
09/03/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220309:nRSI1107Ea&default-theme=true
RNS Number : 1107E Ergomed plc 09 March 2022
PRESS RELEASE
John Dawson CBE Appointed to the Board as Non-Executive Director
Guildford, UK - 9 March 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the
"Company"), a company focused on providing specialised services to the
pharmaceutical industry, today announces that John Dawson, CBE has joined the
Board as an independent Non-Executive Director and Chair of the Audit
Committee.
John Dawson is a highly experienced and globally respected figure in the
healthcare sector. Most recently, he was Chief Executive Officer of Oxford
Biomedica (LSE: OXB) where, during his 13-year tenure, the business grew into
a global market leader in viral vector technologies for cell and gene therapy,
delivered multiple high value partnerships and successfully manufactured the
life-saving Oxford/AstraZeneca COVID-19 vaccine. Under Mr. Dawson's
leadership, Oxford Biomedica's success resulted in it entering the FTSE 250
index in 2020. Subsequently, in the New Year Honours List this year, he was
awarded a CBE for services to UK life science, in recognition of the
unprecedented speed and success at which Oxford Biomedica delivered the
COVID-19 vaccine.
Prior to Oxford Biomedica, Mr. Dawson held various senior executive roles
including at Cephalon Pharmaceuticals where for most of his tenure he was
Managing Director for Europe. Prior to this, he served as the Financial
Director for Serono before its acquisition by Merck. Mr. Dawson holds a BSc in
Mathematics from Swansea University and is a Chartered Accountant.
Dr. Miroslav Reljanović, Executive Chairman of Ergomed, commented: "As a
highly regarded and well-connected figure, John is an outstanding addition to
the Ergomed Board, and his wealth of international experience in the
healthcare industry will be invaluable as the Company continues to grow. The
resounding success of Oxford Biomedica is testament to John's strong
leadership and expert knowledge of the life science sector. We look forward to
utilising his network and benefiting from his extensive experience of working
in the UK public markets."
John Dawson, CBE, said: "Ergomed is fast becoming a leading global
pharmaceutical services provider, which has seen exceptional growth over the
past few years, and which remains at a very exciting stage in its
development. I look forward to working closely with the Board and Senior
Management Team as we continue to build upon this momentum."
The following disclosures are made pursuant to AIM Rule 17 and Schedule 2(g)
of the AIM Rules for Companies:
Mr. John Andrew Dawson, aged 62, holds or has held directorships in the five
years preceding his appointment at Ergomed as follows:
Current Directorships: Directorships in the past five years:
Oxford Biomedica plc PAION AG
Oxford Biomedica (UK) Limited Ocquila Limited
OXB Solutions Limited
There are no further disclosures to be made under Schedule 2(g) of the AIM
Rules for Companies.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis (Nominated Adviser and Joint Broker) Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP (Joint Broker) Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher
Golden
Consilium Strategic Communications - for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal/ Angela Gray ergomed@consilium-comms.com (mailto:ergomed@consilium-comms.com)
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAJPMTTMTTMTBT